We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.64 | 0.17% | 958.64 | 947.23 | 960.00 | 962.10 | 950.27 | 958.00 | 344,073 | 21:15:05 |
1. Name and Address of Reporting Person * Fenimore Christopher R. | 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) VP Controller |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 7/20/2020 | M(1) | 10000 | A | $179.13 | 25277 | D | |||
Common Stock | 7/20/2020 | F(1) | 6291 | D | $655.57 | 18986 | D | |||
Common Stock | 7/20/2020 | M | 2224 | A | $52.03 | 21210 | D | |||
Common Stock | 7/21/2020 | S(1) | 216 | D | $636.56 (2) | 20994 | D | |||
Common Stock | 7/21/2020 | S(1) | 154 | D | $637.88 (3) | 20840 | D | |||
Common Stock | 7/21/2020 | S(1) | 306 | D | $638.51 (4) | 20534 | D | |||
Common Stock | 7/21/2020 | S(1) | 75 | D | $639.64 (5) | 20459 | D | |||
Common Stock | 7/21/2020 | S(1) | 113 | D | $640.61 | 20346 | D | |||
Common Stock | 7/21/2020 | S(1) | 855 | D | $641.58 (6) | 19491 | D | |||
Common Stock | 7/21/2020 | S(1) | 676 | D | $642.39 (7) | 18815 | D | |||
Common Stock | 7/21/2020 | S(1) | 691 | D | $643.49 (8) | 18124 | D | |||
Common Stock | 7/21/2020 | S(1) | 303 | D | $644.57 (9) | 17821 | D | |||
Common Stock | 7/21/2020 | S(1) | 72 | D | $645.33 | 17749 | D | |||
Common Stock | 7/21/2020 | S(1) | 155 | D | $646.82 (10) | 17594 | D | |||
Common Stock | 7/21/2020 | S(1) | 82 | D | $647.79 | 17512 | D | |||
Common Stock | 7/21/2020 | S(1) | 11 | D | $658.0 | 17501 | D | |||
Common Stock | 1432 | I | By 401(k) Plan | |||||||
Common Stock | 1897 | I | By Trust (11) | |||||||
Common Stock | 509 | I | by 2017 GRAT | |||||||
Common Stock | 2284 | I | by 2018 GRAT |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Incentive Stock Option (right to buy) | $52.03 | 7/20/2020 | M | 2224 | (12) | 12/16/2021 | Common Stock | 2224 | $0.0 | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $179.13 | 7/20/2020 | M (1) | 10000 | (13) | 12/14/2022 | Common Stock | 10000 | $0.0 | 13500 | D |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Fenimore Christopher R. 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 | VP Controller |
Signatures | ||
/s/**Christopher R. Fenimore | 7/22/2020 | |
**Signature of Reporting Person | Date |
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions